Copyright ©The Author(s) 2022.
World J Gastroenterol. Mar 7, 2022; 28(9): 881-896
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.881
Table 1 Novel immune therapeutic strategies for clinical chronic hepatitis B treatment
Drug name
HBsAg inhibitorREP-2139ReplicorIIReduce the level of HBsAg[101,102]
HBsAg inhibitorREP-2165ReplicorIIReduce the level of HBsAg (similar to REP-2139)[102]
RIG and NOD agonistSB9200Spring BankIIb/IIIProlonged IFN-α and IFN-β secretion; Reduce hepatitis virus antigen and DNA [107]
TLR7 agonistRO7020531 RocheActivate HBV-specific CD8+ T and Tfh cells; Reduce the frequency of Tregs and MDSCs[108]
TCR-T cellsHBsAg-TCR-T cellsLion TCR PteSafely and efficiently reduced HBsAg levels; Reduced level of HBV DNA and HBsAg[115]
Therapeutic vaccine TG1050TransgeneReduced level of HBV DNA and HBsAg; Long-lasting HBV-specific T cell responses[125]
Therapeutic vaccineHBsAg-HBIG (YIC)National Vaccine and Serum InstituteIIIIncrease the level of IL-2; Long-lasting HBV-specific T-cell responses[126]
Therapeutic vaccineNasvacCIGBIIISustained control of HBV DNA; Clearance of HBeAg[127]
Therapeutic vaccineGS-4774 GileadIIIStrong immune stimulatory effect on T cells[128]